Alluvi, previously BI 4744, presents a significant breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive efficacy in patient trials, possibly outperforming https://alluvi-peptides738125.theisblog.com/profile